Cocrystal Pharma, Inc.
General ticker "COCP" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $12.9M (TTM average)
Cocrystal Pharma, Inc. does not follow the US Stock Market performance with the rate: -10.8%.
Estimated limits based on current volatility of 1.5%: low 0.94$, high 0.97$
Factors to consider:
- Total employees count: 11 as of 2024
- Company does not operate outside North America (retrieved using AI)
- Top business risk factors: Insufficient capital, Clinical trial failure, Regulatory and compliance, Intellectual property risks, Third-party risks
- Price in estimated range
- Earnings for 3 months up through Q1 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [0.60$, 1.61$]
- 2026-12-31 to 2027-12-31 estimated range: [0.62$, 1.62$]
Financial Metrics affecting the COCP estimates:
- Positive: with PPE of -1.3 at the end of fiscal year the price was neutral
- Negative: negative Operating cash flow
- Positive: Investing cash flow per share per price, % of -0.11 > -0.60
- Negative: negative Operating income
- Positive: Inventory ratio change, % of 0 <= 0
- Positive: Shareholder equity ratio, % of 65.19 > 64.23
Short-term COCP quotes
Long-term COCP plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $18.56MM | $17.88MM | $9.02MM |
| Operating Income | $-18.56MM | $-17.88MM | $-9.02MM |
| Non-Operating Income | $0.57MM | $0.37MM | $0.19MM |
| R&D Expense | $15.17MM | $12.54MM | $5.05MM |
| Income(Loss) | $-17.98MM | $-17.50MM | $-8.83MM |
| Net Income(Loss)* | $-17.98MM | $-17.50MM | $-8.83MM |
| Stockholders Equity | $26.38MM | $9.52MM | $6.33MM |
| Assets | $31.26MM | $13.46MM | $9.71MM |
| Operating Cash Flow | $-14.67MM | $-16.48MM | $-8.19MM |
| Capital expenditure | $0.12MM | $0.01MM | $0.01MM |
| Investing Cash Flow | $-0.12MM | $-0.01MM | $-0.01MM |
| Financing Cash Flow | $3.99MM | $0.00MM | $5.37MM |
| Earnings Per Share** | $-1.86 | $-1.72 | $-0.78 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.